These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 1424129

  • 1. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared.
    Bettica P, Moro L, Robins SP, Taylor AK, Talbot J, Singer FR, Baylink DJ.
    Clin Chem; 1992 Nov; 38(11):2313-8. PubMed ID: 1424129
    [Abstract] [Full Text] [Related]

  • 2. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis.
    Bettica P, Taylor AK, Talbot J, Moro L, Talamini R, Baylink DJ.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):542-6. PubMed ID: 8636265
    [Abstract] [Full Text] [Related]

  • 3. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.
    Del Campo MT, González-Casaus ML, Aguado P, Bernad M, Carrera F, Martínez ME.
    Osteoporos Int; 1999 Feb; 9(5):449-54. PubMed ID: 10550465
    [Abstract] [Full Text] [Related]

  • 4. Urinary output of hydroxylysine glycosides and pyridinium cross-links in detecting rat bone collagen turnover rate.
    Grazioli V, Alfano M, Stenico A, Casari E.
    FEBS Lett; 1996 Jun 17; 388(2-3):134-8. PubMed ID: 8690072
    [Abstract] [Full Text] [Related]

  • 5. Galactosylhydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy.
    Marabini R, Sirtori P, Chionna R, Barzizza L, Rubinacci A.
    J Endocrinol Invest; 1996 Mar 17; 19(3):154-8. PubMed ID: 8743280
    [Abstract] [Full Text] [Related]

  • 6. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.
    Uebelhart D, Gineyts E, Chapuy MC, Delmas PD.
    Bone Miner; 1990 Jan 17; 8(1):87-96. PubMed ID: 2106358
    [Abstract] [Full Text] [Related]

  • 7. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis.
    Eastell R, Colwell A, Hampton L, Reeve J.
    J Bone Miner Res; 1997 Jan 17; 12(1):59-65. PubMed ID: 9240726
    [Abstract] [Full Text] [Related]

  • 8. Galactosyl hydroxylysine and deoxypyridinoline: a methodological comparison.
    Bettica P, Baylink DJ, Moro L.
    Eur J Clin Chem Clin Biochem; 1993 Jul 17; 31(7):459-65. PubMed ID: 8399787
    [Abstract] [Full Text] [Related]

  • 9. Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: A potential marker of bone fragility.
    Lo Cascio V, Bertoldo F, Gambaro G, Gasperi E, Furlan F, Colapietro F, Lo Cascio C, Campagnola M.
    J Bone Miner Res; 1999 Aug 17; 14(8):1420-4. PubMed ID: 10457275
    [Abstract] [Full Text] [Related]

  • 10. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
    Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R.
    J Bone Miner Res; 1993 Jul 17; 8(7):881-9. PubMed ID: 8352070
    [Abstract] [Full Text] [Related]

  • 11. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L.
    J Bone Miner Res; 1996 Aug 17; 11(8):1176-84. PubMed ID: 8854254
    [Abstract] [Full Text] [Related]

  • 12. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation.
    Krane SM, Kantrowitz FG, Byrne M, Pinnell SR, Singer FR.
    J Clin Invest; 1977 May 17; 59(5):819-27. PubMed ID: 404321
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal antibody assay for free urinary pyridinium cross-links.
    Gomez B, Ardakani S, Evans BJ, Merrell LD, Jenkins DK, Kung VT.
    Clin Chem; 1996 Aug 17; 42(8 Pt 1):1168-75. PubMed ID: 8697572
    [Abstract] [Full Text] [Related]

  • 14. Biochemical markers of bone turnover for the clinical assessment of bone metabolism.
    Taylor AK, Lueken SA, Libanati C, Baylink DJ.
    Rheum Dis Clin North Am; 1994 Aug 17; 20(3):589-607. PubMed ID: 7984780
    [Abstract] [Full Text] [Related]

  • 15. Development of an immunoassay for urinary galactosylhydroxylysine.
    Leigh SD, Ju HS, Lundgard R, Daniloff GY, Liu V.
    J Immunol Methods; 1998 Nov 01; 220(1-2):169-78. PubMed ID: 9839938
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.
    Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ.
    Eur J Clin Invest; 1991 Jun 01; 21(3):310-5. PubMed ID: 1909635
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption.
    Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG.
    Osteoporos Int; 1993 Sep 01; 3(5):255-60. PubMed ID: 8400607
    [Abstract] [Full Text] [Related]

  • 18. Galactosyl hydroxylysine in assessment of Paget's bone disease.
    Michalsky M, Stepan JJ, Wilczek H, Formankova J, Moro L.
    Clin Chim Acta; 1995 Jan 31; 234(1-2):101-8. PubMed ID: 7758208
    [Abstract] [Full Text] [Related]

  • 19. Ovariectomy in the rat induces a rapid increase in the urinary excretion of hydroxylysine glycosides and non-reducible crosslink residues.
    Casari E, Alfano M, Valente M, Clarke GD, Ferni G, Grazioli B.
    Osteoporos Int; 1997 Jan 31; 7(6):539-43. PubMed ID: 9604049
    [Abstract] [Full Text] [Related]

  • 20. Urinary bone resorption markers in patients with metabolic bone disorders.
    Ohishi T, Kushida K, Takahashi M, Kawana K, Yagi K, Kawakami K, Horiuchi K, Inoue T.
    Bone; 1994 Jan 31; 15(1):15-20. PubMed ID: 8024845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.